drugset / Trial / NCT06575075
Pilot Study of RR-HNK in OCD
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to understand how RR-HNK works in the brain to bring about a reduction in OCD symptoms.
Timeline
- Start
- 2026-01-23
- Primary completion
- 2028-11-30
- Completion
- 2029-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RR-HNK | Unknown | 0.25 mg/kg | Intravenous |
| Subject | RR-HNK | Unknown | 0.5 mg/kg | Intravenous |